Teicoplanin

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Teicoplanin is a drug catalogued in DrugCentral. Recorded indications include Staphylococcal infectious disease.

• Indications: Staphylococcal infectious disease.
• ATC code: J01XA02 (Glycopeptide antibacterials).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Staphylococcal infectious disease

ATC classification

ATC code	Therapeutic hierarchy
J01XA02	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER ANTIBACTERIALS › Glycopeptide antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug reaction with eosinophilia and systemic symptoms	471.2
Pyrexia	248.7
Multiple organ dysfunction syndrome	247.6
Thrombocytopenia	205.6
Neutropenia	165.9
Septic shock	165.5
Febrile neutropenia	142.7
Rash maculo-papular	140.2
Eosinophilia	132.0
Cross sensitivity reaction	131.2
Acinetobacter infection	123.3
Drug resistance	119.8

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 61036-62-2
• InChIKey: —
• PubChem CID: 133065662

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Teicoplanin used for?

DrugCentral lists the following indications for Teicoplanin: Staphylococcal infectious disease.

Sources

• DrugCentral drug card 2998 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297166 — compound record and bioactivity
• PubChem CID 133065662 — chemical identifiers
• DrugBank DB06149 — drug record
• FDA UNII 4U3D3YY81M — substance identity
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.